TEL AVIV UNIVERSITY

NeuroSense Therapeutics reports completion of 18-month Phase 2b PARADIGM study, highlighting PrimeC's potential to slow ALS progression. Positive FDA feedback supports Phase 3 study commencement in mid-2025. The company plans early commercialization in Canada with a potential 2026 launch. NeuroSense secured a $5 million private placement in December 2024, and Phase 2b results were presented at the 2024 ALS/MND Symposium. The company expects to submit a dossier to Health Canada in Q2 2025.

Case Western Reserve University researchers helped uncover evidence of ritualistic gatherings in Manot Cave, Galilee, Israel, dated to 35,000 years ago. The cave, used by Neanderthals and humans, features a cavern with a turtle-engraved rock possibly used for rituals. Dental students played a crucial role in identifying bone fragments during the excavation.

E. Madan led experiments, data analysis, and manuscript writing. A.M.P., V.V., A.K., and P.B. contributed to experiments, data analysis, and manuscript preparation. J.W. handled biostatistical analysis and data interpretation. T.B. and D.A. focused on microscopy, data interpretation, and figure preparation. P.C.M., G.B., M.D.B., I.D., H.K., and D.O. assisted with biostatistical analysis and data interpretation. A. Gogna and A.B. helped with figure preparation and live-cell videos. M.L.P., M.Y., D.Z., S.P., S.K., K.B., P.M., I.C., E.A.F., A.K.P., S.M., C.J.P., A.L., M.N., S.C., K.G., K.C.G., and K.S.S. contributed to pathology data collection and analysis. T.F.A., E.G., A. Gustafsson, G.L., L.N., E.Y., and R.S.-F. worked on 3D scaffold and organoid experiments. K.D.P.D. assisted with PDX experiments. N.M., M.J.P., K.J.-J., and S.H. focused on exosome biology experiments. Z.S. and W.L.R. worked on multiplexing experiments. M.B. and P.J. handled FISH experiments. H.O.R., F.A.T., and R.B. contributed to MR imaging data analysis. K.G.A., J.A., G.X., G.S., and S. Singh designed and produced mAbs. S.D., C.L.d.S., A.M.F., D.T., S.R.G., K.P., G.G., G.L.W.G.R., and H.W. edited the manuscript. A.M.H., A.R., and C.L. worked on mass spec analysis. A.S. and P.B.F. provided laboratory resources and collaboration. G.M.C., Y.L., A.L.O., L.L., and A.A.T. handled CRISPR-off experiments. A.S.P., U.M., R.D., A.K.G., K.S., and D. Chelmow contributed to ovarian cancer expertise. R.P., J.K., S.R., H.R., S. Sayeed, K.P.K., D. Connolly, K.P.N., M.O.I., M.P.K., C.M., M.A., A.L.-B., D.J., K.D.M., A. Tzankov, S.B., E.A.R., and R.C.M. assisted with pathology data collection. A. Tsung and D.S. fostered clinical collaborations. J.T. provided mouse tumor models and funding. A.P.S., R.W., K.J.W., and E. Moreno helped with manuscript writing and funding. R.G. designed the study, organized collaborations, and provided overall supervision and funding.

Tel Aviv University researchers developed a COVID-19 vaccine that can be stored at room temperature and administered as a nasal spray, breaking Pfizer and Moderna's duopoly. The nanovaccine, composed of 200-nanometer particles, trains the immune system against all common variants and doesn't require cold storage, making it ideal for developing countries.

FDA-funded study by Lori Quinn and Jamie Adams uses digital sensors to track early Huntington’s symptoms, aiming to develop affordable outcome measures for drug trials, with potential applications for other neurodegenerative diseases.

Tel Aviv University researchers discovered NMDA receptors (NMDARs) maintain brain stability, explaining ketamine's fast-acting antidepressant effect. Their study, combining lab experiments, mouse tests, and computer modeling, suggests NMDARs could lead to new treatments for depression, Alzheimer’s, and epilepsy.

NurExone (OTC:NRXBF) develops ExoPTEN for acute spinal cord injuries, targeting a 50,000-case global market. ExoPTEN received Orphan Medicinal Product Designation from the EMA, offering incentives like ten years of market exclusivity. The FDA also granted Orphan Drug Designation in 2023, providing seven years of market exclusivity. Initial test results in rats showed significant functional recovery, supporting the company's potential.

Hyperbaric oxygen therapy (HBOT) significantly reduces PTSD symptoms in veterans with combat-associated PTSD (CA-PTSD), improving clinical outcomes and brain connectivity, as demonstrated in a randomized, sham-controlled trial.

Oriental hornets (Vespa orientalis) exhibit unparalleled alcohol tolerance, consuming up to 80% ethanol without health or behavioral changes. Their unique genetic makeup, featuring multiple copies of the alcohol dehydrogenase gene, enables rapid alcohol metabolism, offering potential applications in medicine, pest control, evolutionary biology, and biotechnology.